Related Experiment Videos
Tamoxifen therapy in advanced/recurrent endometrial carcinoma
1Gynaecology Unit, Peter MacCallum Cancer Institute, Melbourne, Australia.
Gynecologic Oncology
|January 1, 1989
Summary
Tamoxifen shows promise for advanced endometrial cancer, with a 20% response rate in patients. Responders experienced significantly longer survival, and the treatment was well-tolerated with minimal toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Endometrial carcinoma is a significant gynecologic malignancy.
- Advanced or recurrent stages often present treatment challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of Tamoxifen in patients with advanced/recurrent endometrial carcinoma.
Main Methods:
- A cohort of forty-nine patients received Tamoxifen (20 mg, twice daily).
- Response rates and survival outcomes were assessed.
Main Results:
- A 20% overall response rate was observed (6 complete, 4 partial responses).
- Responders had a median survival of 34 months versus 6 months for nonresponders.
- Tamoxifen demonstrated minimal toxicity in this patient group.
Conclusions:
- Tamoxifen is an effective treatment option for a subset of patients with advanced/recurrent endometrial carcinoma.
- The drug offers a survival benefit for responders with acceptable safety profile.